We thrive on products that have limited competition: Top Sun Pharma execs

In a Q&A, the firm's US business head and its group CFO talk about their plans to scale the specialty products business further, and dwell on the company's strategies post-pandemic

India’s largest drugmaker by market share, Sun Pharmaceutical Industries, has seen its specialty products pay off, with the portfolio growing 11 per cent YoY in the second quarter, to $201 million. Speaking to Sohini Das, Sun Pharma’s CEO of US business, Abhay Gandhi, and Group CFO C S Muralidharan, talk about their plans to scale this business further. Edited excerpts:

Are patient footfalls in clinics back to pre-Covid-19 levels in the US?

Abhay Gandhi: The footfalls in clinics are not back to normal, but medical representatives visiting doctors physically is back to pre-Covid-19 levels now. It would take you 2-3